My point is that I view this stock as much more than a 250
My point is that I view this stock as much more than a 250 share investment and hope it pans out to an $8750 return.
That is like the owners of Secretariat hoping that one day they would make $10,000 off his winnings just prior to the Triple Crown. They had the vision to see that they had perhaps the greatest racehorse of all time.
I see IPIX as a Secretariat of the biotech industry and as such I expect the same type of returns that the Penny family received from Secretariat.
Guess it all boils down to vision. As stated in "Patriot Games" if "aim small, miss small" is your cup of tea invest about $150 in IPIX and hope for $8750. If your vision is to aim big and reach out to grasp the golden ring, then you bet large and expect massive returns. I believe the trial data to date and the interest from 20 BP CDAs makes a very large investment in IPIX a prudent investment, especially at this stage of the game. Note: A large investment is subjective for each investor's financial situation and if all they can afford is $250 or so, then I applaud them for taking the risk.
$35 a share is somewhere around a buyout of $8B for IPIX. Hell, Prurisol for psoriasis alone, even with P2b clinical data being only slightly better than 200 dosage arm, IMO should result in revenues of $50B or so over the life of the Prurisol patent.
So when I see people valuing IPIX like a one drug, one indication, at a pre-clinical or pre-Phase I trial stage, with maybe one BP showing interest in them and they needing funds immediately to prevent bankruptcy, I shudder.
If one can't see the true value of IPIX, then IMO they don't deserve to be in this stock and make money from its success.
11
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Better Home & Finance's Financial Freefall The rollercoaster of stock markets sees plenty of ups and downs, but when you tack on a securities class action, it’s more like getting stuck on a loop. That’s exactly where Better Home & Finance (NASDAQ: BETR) finds itself after the wheels came off in their Q1 2026 report. A gut-wrenching 75% jump in their net loss tells you...
Continue Reading
Cytrellis Partners with University of Miami The announcement from Cytrellis Biosystems is drawing some attention. The company's jumped into a new partnership with the University of Miami School of Nursing and Health Studies, looking to jazz up their Aesthetic Medicine Certificate Program. The kicker here is the introduction of Cytrellis' ellacor® system, a fancy bit of...
Continue Reading
Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...
Continue Reading
CapCut's Recognition in the Creative AI Space The shift towards comprehensive creative platforms is taking the tech world by storm, and CapCut's latest nod from Software Experts is turning heads in 2026 with its ambitious integration. Touted for its versatility, CapCut serves creative projects that need an amalgamation of video, image, and audio elements. Tackling the...
Continue Reading
Cracks in Cerebras' Processor Promises? When you dance with high-stakes tech stocks, sometimes you end up stepping on a few toes. This seems to ring true as Cerebras Systems (CBRS) dances its way into hot water. Allegations from Culper Research suggest their fancy AI processors, which are supposed to be the poster children of reliability, might bow out early. Digging...
Continue Reading
Pledge for Vision In a world where a staggering number of folks wrestle with avoidable vision issues, Orbis International is stepping up to the plate with ambitions that feel as bold as they are necessary. Orbis is pouring a significant $32 million into its mission to beef up eye health systems, train a small army of professionals, and apply AI in eye care. Their big bet...
Continue Reading
Encouraging Signs from Phrontline's TJ101 ADC Trials In the high-stakes race to outsmart cancer, Phrontline Biopharma is banking on TJ101, their star investigational bispecific antibody-drug conjugate (ADC). The recent results shared at the ESMO Congress 2026 are stirring up quite a bit of chatter. Urothelial Carcinoma and Beyond Now, picture this: six of eight evaluable...
Continue Reading
The Green Methanol Boom Folks, the money's about to get greener—greener methanol, that is. We’re talking about a market that’s set to explode from a humble $3.46 billion in 2026 to a jaw-dropping $20.11 billion by 2032. With a hefty CAGR of 34.1%, it seems like investors might want to buckle up for a bullish ride in this eco-friendly venture. Why Green Methanol?...
Continue Reading
Atlas Expands Culinary Cruise Horizons in 2027 Now here's a twist for you—cuisine meets cruise in a hefty blend of sail, chew, and swirl. Atlas Ocean Voyages is practically throwing a gourmet party on water with their 2027 Epicurean Expeditions. They're unfurling the sails alongside chef heavyweights like Crista Luedtke and wine maestro Anthony Giglio. Imagine a cruise...
Continue Reading
Solid Performance Boosts Confidence Gates Industrial came out swinging with their third-quarter results for 2026, showing some financial prowess that would make even the skeptics raise an eyebrow. Net sales climbed to a hefty $903.6 million, advancing 5.6% from the same time last year. It's not just smoke—core sales jumped 5.5%, signaling they're doing a bit more than...
Continue Reading
Top 5 Most Recently Viewed Articles
Meme Coins on the Rise: Will PEPE, WIF, and POPCAT Lead the Charge? Several analysts are suggesting that the emerging meme coins PEPE, WIF, and POPCAT could be primed for exceptional growth and outperformance against well-known competitors like Shiba Inu and Dogecoin. With mounting excitement surrounding these digital assets, traders are closely analyzing price movements...
Continue Reading
AppLovin's Recent Momentum in E-Commerce AppLovin Corp (NASDAQ: APP) is experiencing notable momentum as it expands its e-commerce capabilities. This growth is primarily attributed to a significant increase in the number of merchants adopting its Axon advertising technology, which has raised expectations for a potential upside in the fourth quarter. Recent analysis...
Continue Reading
Exploring the Rise of the Functional Gummies Market The functional gummies market is set to witness significant growth as it responds to evolving consumer demands for health-focused products. This market capitalizes on the intersection of nutrition, wellness, and enjoyment, providing essential nutrients in a format that appeals to a wide audience. The transition towards...
Continue Reading
Cavvy Energy Reports Strong Q3 2025 Financial Performance CALGARY, Alberta — Cavvy Energy Ltd. (TSX: CVVY) has released its financial and operational results for the third quarter of 2025, showcasing impressive growth and resilience amidst market challenges. In this quarter, the company reported a production rate of 23,956 barrels of oil equivalent per day (boe/d) and a...
Continue Reading
AI tools have made life easier in so many ways that one sometimes overlooks their risks. For financial analysis and guidance, an empathetic and supportive AI chatbot may feel like the perfect ally. But that illusion can be damaged if you find business or personal finance information exposed or misused. If you currently use AI tools for financial analysis or assessments,...
Continue Reading